CARM · As filed with the SEC
Carisma Therapeutics balance sheet, by quarter
The statement as Carisma Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Unaudited Consolidated Balance Sheets · USD
| USD | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 |
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 2,777,000 | 1,999,000 | 7,740,000 | 17,909,000 |
| Prepaid expenses and other assets | 3,090,000 | 2,285,000 | 2,901,000 | 5,916,000 |
| Assets held for sale | 3,000 | 11,000 | 3,313,000 | — |
| Total current assets | 5,870,000 | 4,295,000 | 13,954,000 | 23,825,000 |
| Property and equipment, net | 0 | 0 | 0 | 4,385,000 |
| Right of use assets - operating leases | 684,000 | 717,000 | 1,999,000 | 2,040,000 |
| Deferred financing costs | 0 | 0 | 0 | 208,000 |
| Total assets | 6,554,000 | 5,012,000 | 15,953,000 | 30,458,000 |
| Liabilities and Stockholders' Deficit | ||||
| Current liabilities: | ||||
| Accounts payable | 5,571,000 | 4,757,000 | 3,251,000 | 2,081,000 |
| Accrued expenses | 1,088,000 | 2,528,000 | 4,705,000 | 7,448,000 |
| Deferred revenue | 0 | 0 | 0 | 3,729,000 |
| Operating lease liabilities | 153,000 | 703,000 | 998,000 | 832,000 |
| Finance lease liabilities | 0 | 349,000 | 640,000 | 905,000 |
| Other current liabilities | 0 | 613,000 | 853,000 | 1,060,000 |
| Total current liabilities | 6,812,000 | 8,950,000 | 10,447,000 | 16,055,000 |
| Deferred revenue | 0 | 41,250,000 | 41,250,000 | 41,250,000 |
| Operating lease liabilities | 609,000 | 648,000 | 687,000 | 724,000 |
| Finance lease liabilities | 0 | 0 | 0 | 20,000 |
| Other long-term liabilities | 0 | 169,000 | 231,000 | 318,000 |
| Total liabilities | 7,421,000 | 51,017,000 | 52,615,000 | 58,367,000 |
| Stockholders' deficit: | ||||
| Preferred stock $0.001 par value, 5,000,000 shares authorized, none issued or outstanding | — | 0 | 0 | 0 |
| Common stock $0.001 par value, 350,000,000 shares authorized, 41,788,096 and 41,750,109 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 41,000 | 41,000 | 41,000 | 41,000 |
| Additional paid-in capital | 278,994,000 | 278,573,000 | 278,142,000 | 277,629,000 |
| Accumulated deficit | (279,902,000) | (324,619,000) | (314,845,000) | (305,579,000) |
| Total stockholders' deficit | (867,000) | (46,005,000) | (36,662,000) | (27,909,000) |
| Total liabilities and stockholders' deficit | 6,554,000 | 5,012,000 | 15,953,000 | 30,458,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.